ABVC BioPharma Amends Financial Statement Reliance Filing

Ticker: ABVC · Form: 8-K/A · Filed: May 2, 2025 · CIK: 1173313

Abvc Biopharma, Inc. 8-K/A Filing Summary
FieldDetail
CompanyAbvc Biopharma, Inc. (ABVC)
Form Type8-K/A
Filed DateMay 2, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: amendment, financial-reporting, non-reliance

TL;DR

ABVC BioPharma's financials might be shaky - they're amending a filing about not relying on old reports.

AI Summary

ABVC BioPharma, Inc. filed an 8-K/A on May 2, 2025, to amend a previous filing concerning the non-reliance on previously issued financial statements. This amendment relates to events that occurred on April 15, 2025, indicating a potential issue with their past financial reporting or audit.

Why It Matters

This filing suggests potential inaccuracies in ABVC BioPharma's past financial statements, which could impact investor confidence and the company's reported financial health.

Risk Assessment

Risk Level: medium — Amendments regarding non-reliance on financial statements often signal underlying accounting or reporting issues that could affect the company's valuation.

Key Players & Entities

  • ABVC BIOPHARMA, INC. (company) — Registrant
  • 001-40700 (company) — SEC File Number
  • 26-0014658 (company) — IRS Employer Identification No.
  • Nevada (company) — State of Incorporation
  • April 15, 2025 (date) — Date of earliest event reported
  • May 2, 2025 (date) — Date of Report

FAQ

What specific financial statements are no longer reliable?

The filing does not specify which particular financial statements are affected, only that there is a non-reliance on previously issued financial statements or a related audit report or completed interim review.

What is the reason for the non-reliance on previously issued financial statements?

The filing is an amendment to a previous report and does not provide the specific reasons for the non-reliance on the financial statements.

When was the original report filed that this 8-K/A is amending?

The filing does not explicitly state the date of the original report being amended, but it is an 8-K/A filed on May 2, 2025, concerning events as of April 15, 2025.

What is the company's primary business?

ABVC BioPharma, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

Has ABVC BioPharma changed its name previously?

Yes, ABVC BioPharma, Inc. was formerly known as American BriVision (Holding) Corp, METU BRANDS, INC., and ECOLOGY COATINGS, INC.

Filing Details

This Form 8-K/A (Form 8-K/A) was filed with the SEC on May 2, 2025 regarding ABVC BIOPHARMA, INC. (ABVC).

View full filing on EDGAR

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.